| Assessment Status | Rapid Review Complete |
| HTA ID | 22029 |
| Drug | Semaglutide |
| Brand | Wegovy® |
| Indication | Is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity), or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. |
| Assessment Process | |
| Rapid review commissioned | 09/05/2022 |
| Rapid review completed | 09/06/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of semaglutide (Wegovy®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The Applicant has withdrawn their pricing and reimbursement application for semaglutide (Wegovy®) solution for injection in pre-filled pen (PFP) (4 pack), therefore the cost-effectiveness of this technology could not be proven. March 2025.
